These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12349884)

  • 1. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?
    Dolan P; Edlin R
    J Health Econ; 2002 Sep; 21(5):827-43. PubMed ID: 12349884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin.
    Hansen BO; Hougaard JL; Keiding H; Østerdal LP
    J Health Econ; 2004 Sep; 23(5):887-98. PubMed ID: 15353184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-social welfare functions: a reply to Hansen et al.
    Edlin R
    J Health Econ; 2004 Sep; 23(5):899-905. PubMed ID: 15353185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring the social importance of concentration or dispersion of individual health benefits.
    Rodríguez-Míguez E; Pinto-Prades JL
    Health Econ; 2002 Jan; 11(1):43-53. PubMed ID: 11788981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 7. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measures of efficiency in healthcare: QALMs about QALYs?
    Schlander M
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(3):214-26. PubMed ID: 20608250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QALYs, standard gambles, and the expected budget constraint.
    Blomqvist A
    J Health Econ; 2002 Mar; 21(2):181-95. PubMed ID: 11939237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
    Birch S; Gafni A
    J Health Econ; 1992 Oct; 11(3):279-96. PubMed ID: 10122540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care evaluation, utilitarianism and distortionary taxes.
    Calcott P
    J Health Econ; 2000 Sep; 19(5):719-30. PubMed ID: 11184801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
    Culyer AJ; Chalkidou K
    Value Health; 2019 Jan; 22(1):99-103. PubMed ID: 30661640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On individual preferences and aggregation in economic evaluation in healthcare.
    Liljas B; Lindgren B
    Pharmacoeconomics; 2001; 19(4):323-35. PubMed ID: 11383750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the welfare theoretic foundation of CEA: comment.
    Breyer F
    Eur J Health Econ; 2010 Dec; 11(6):595-6; discussion 597-8. PubMed ID: 20949303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.
    Liljas B
    Eur J Health Econ; 2010 Feb; 11(1):5-13. PubMed ID: 19255794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?
    Birch S; Donaldson C
    Soc Sci Med; 2003 Mar; 56(5):1121-33. PubMed ID: 12593883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In defence of societal sovereignty: a comment on Nyman 'the inclusion of survivor consumption in CUA'.
    Richardson JR; Olsen JA
    Health Econ; 2006 Mar; 15(3):311-3; discussion 319-22. PubMed ID: 16389655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.